SARS-CoV-2 envelope protein identified as target for antiviral drugs


July 27, 2020 -- SARS-CoV-2 envelope protein identified as target for antiviral drugs

 SARS-CoV-2 envelope protein identified as target for antiviral drugs
 
Web version

scienceboard.net
July 27, 2020
Top Stories
SARS-CoV-2 envelope protein identified as target for antiviral drugs
Comparison of the SARS-CoV-2 genome with other betacoronaviruses can provide useful information on how drugs targeting other coronaviruses may improve outcomes for COVID-19 patients. The analysis was presented in a July 27 Frontiers in Cellular and Infection Microbiology article.  

 
Moderna, NIH to begin phase III testing of COVID-19 vaccine
Moderna has begun a phase III clinical trial evaluating its messenger RNA (mRNA)-1273 COVID-19 vaccine candidate. The trial is expected to enroll approximately 30,000 healthy adult volunteers.  

 
SARS-CoV-2 disguises its own genetic material to facilitate infection
The SARS-CoV-2 virus is able to camouflage itself to promote viral replication, as revealed by structural details of proteins on the surface of the virus. Researchers discovered an enzyme that they believe could be an important target for antiviral drug development, according to a July 14 Nature Communications report.  

 


Biochemistry
Novavax, Fujifilm begin large-scale manufacturing of COVID-19 vaccine
Novavax and Fujifilm Diosynth have signed an agreement covering the bulk manufacture of Novavax's COVID-19 vaccine candidate, Nvx-CoV2373, at Fujifilm's Morrisville, NC facility.  

 
Synaffix, ADC Therapeutics collaborate on antibody drug conjugates
Synaffix and ADC Therapeutics have expanded an existing collaboration to explore additional applications of Synaffix's site-specific conjugation technologies.  

 
Cancer & Disease Research
Pfizer, BioNTech get $1.95B for SARS-CoV-2 vaccine
Pfizer and BioNtech have inked an agreement with the U.S. Department of Health and Human Services and the Department of Defense, as part of the federal government's Operation Warp Speed, to deliver 300 million doses of the BNT162 vaccine candidate in 2021.  

 
Cell Biology
New tools rapidly detect anti-SARS-CoV-2 antibodies
New tools using surrogate viruses may be useful for rapid testing to determine whether antibodies effectively neutralize SARS-CoV-2. The viral vector-based platform approach was published in the Journal of Experimental Medicine on July 21.  

 
Drug Discovery & Development
SARS-CoV-2 envelope protein identified as target for antiviral drugs
Comparison of the SARS-CoV-2 genome with other betacoronaviruses can provide useful information on how drugs targeting other coronaviruses may improve outcomes for COVID-19 patients. The analysis was presented in a July 27 Frontiers in Cellular and Infection Microbiology article.  

 
Certara launches COVID-19 clinical database
Centara has launched the COVID-19 Clinical Outcomes database, which provides information on the results of clinical trials and observational studies on the novel coronavirus.  

 
Addressing the COVID-19 challenge with computer modeling & simulation
Each day, we wake up hoping for positive news about vaccines and therapies to combat COVID-19. More than 70 candidate molecules are being evaluated for repurposing to treat COVID-19. This number will grow thanks to the use of new combination therapies discovered under an aggressive, disciplined, and quantitative approach to evaluating candidates called model-informed drug development.  

 
Ampio enrolls patients in COVID-19 clinical trial
Ampio Pharmaceuticals has begun patient enrollment in its COVID-19 phase I clinical trial to evaluate its Ampion drug candidate.  

 
Genomics
SARS-CoV-2 disguises its own genetic material to facilitate infection
The SARS-CoV-2 virus is able to camouflage itself to promote viral replication, as revealed by structural details of proteins on the surface of the virus. Researchers discovered an enzyme that they believe could be an important target for antiviral drug development, according to a July 14 Nature Communications report.  

 
Immunology
Moderna, NIH to begin phase III testing of COVID-19 vaccine
Moderna has begun a phase III clinical trial evaluating its messenger RNA (mRNA)-1273 COVID-19 vaccine candidate. The trial is expected to enroll approximately 30,000 healthy adult volunteers.  

 
Cel-Sci reports positive early results of COVID-19 LEAPS conjugate
Cel-Sci completed animal testing using its Ligand Epitope Antigen Presentation System (LEAPS) COVID-19 conjugate, which means the firm can now move into animal challenge studies with the live SARS-CoV-2 virus.  

 
Intravacc, Leiden University explore vaccine quality control without animals
Intravacc has collaborated with Leiden Academic Center for Drug Research at Leiden University to find alternatives for the use of lab animals in vaccine quality control.  

 
What Your Colleagues are Buzzing About
Scientists urge that surveillance of a new SARS-CoV-2 variant is necessary
  
SARS-CoV-2 Nsp1 protein effectively blocks host antiviral defenses
  



• Do not reply to this e-mail as it was sent automatically from an unmonitored account.
  
•Unsubscribe from the Letter from the Editor.
  
•Reset your password.
  
•Contact scienceboard.net support.
  
•scienceboard.net Privacy Policy.
  
•Email sent to: .

scienceboard.net, 1350 North Kolb Road, Suite 215, Tucson, AZ 85715 USA - +1 520-298-1000
Copyright 2020 scienceboard.net. All Rights Reserved.
 
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.